ANALYSIS OF CLINICALLY ACTIONABLE PREEMPTIVE PHARMACOGENOMIC (PGx) INFORMATION TO IMPACT IN-HOSPITAL PRESCRIBING.

被引：0
|
作者：
Lee, Y. [1 ]
Danahey, K. [1 ]
Ratain, M. J. [1 ]
Meltzer, D. O. [1 ]
O'Donnell, P. H. [1 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OIII-4
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] ANALYSIS OF ADULT IN-HOSPITAL MEDICATIONS FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) INFORMATION.
    Lee, Y.
    Danahey, K.
    Moscoe, G.
    Kreidich, L.
    Ratain, M. J.
    Meltzer, D. O.
    O'Don-Donnell, P. H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S34 - S34
  • [2] Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing
    Lee, Yee Ming
    Danahey, Keith
    Knoebel, Randall W.
    Ratain, Mark J.
    Meltzer, David O.
    O'Donnell, Peter H.
    [J]. PHARMACOGENETICS AND GENOMICS, 2019, 29 (02): : 23 - 30
  • [3] Identification of clinically actionable drug-drug-gene interactions that impact pharmacogenomic prescribing
    Lee, Yee Ming
    Agolini, Emanuele
    Danahey, Keith
    Yukman, Patrick
    Borden, Brittany
    Leung, Edward
    Yeo, Kiang-Teck
    O'Donnell, Peter
    Ratain, Mark
    [J]. PHARMACOTHERAPY, 2016, 36 (12): : E266 - E267
  • [4] EVALUATING RACIAL POPULATION (POP)-SPECIFIC RISK FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) GUIDANCE.
    Rizk, A.
    Danahey, K.
    Schierer, E.
    Perera, M.
    Meltzer, D.
    Ratain, M.
    O'Donnell, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S19 - S19
  • [5] EVALUATING RACIAL POPULATION (POP)SPECIFIC RISK FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) GUIDANCE.
    Rizk, A.
    Danahey, K.
    Schierer, E.
    Perera, M.
    Meltzer, D.
    Ratain, M.
    O'Donnell, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S58 - S58
  • [6] PREVALENCE OF CLINICALLY ACTIONABLE GENOTYPE RESULTS FOR ONCOLOGY DRUG-GENE INTERACTIONS (DGIS) AMONG PATIENTS (PTS) WITH PREEMPTIVE PHARMACOGENOMIC (PGX) TESTING.
    Reizine, N.
    Danahey, K.
    George, D.
    House, L.
    van Wijk, X.
    Yeo, K.
    Ratain, M.
    Vokes, E.
    O'Donnell, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S68 - S68
  • [7] Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
    Van Driest, S. L.
    Shi, Y.
    Bowton, E. A.
    Schildcrout, J. S.
    Peterson, J. F.
    Pulley, J.
    Denny, J. C.
    Roden, D. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) : 423 - 431
  • [8] Evaluation of popular drug information resources on clinically useful and actionable pharmacogenomic information
    Chang, Jennifer S.
    Duyen-Anh Pham
    Dang, Maithao T.
    Lu, Yiting
    VanOsdol, Sheri
    Shin, Jaekyu
    [J]. JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 2016, 104 (01) : 58 - 61
  • [9] Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing
    Reizine, Natalie M.
    Danahey, Keith
    Truong, Tien M.
    George, David
    House, Larry K.
    Karrison, Theodore G.
    van Wijk, Xander M. R.
    Yeo, Kiang-Teck J.
    Ratain, Mark J.
    O'Donnell, Peter H.
    [J]. CANCER, 2022, 128 (08) : 1649 - 1657
  • [10] CLINICAL IMPACT OF AN ON-DEMAND GENOMIC PRESCRIBING SYSTEM (GPS) FOR PHARMACOGENOMIC (PGx) RESULTS DELIVERY
    Wadhwa, N.
    Danahey, K.
    Cao, H.
    Saner, D.
    Ratain, M.
    O'Donnell, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S14 - S14
12345